These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 22095692)

  • 1. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
    Johri A; Calingasan NY; Hennessey TM; Sharma A; Yang L; Wille E; Chandra A; Beal MF
    Hum Mol Genet; 2012 Mar; 21(5):1124-37. PubMed ID: 22095692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
    Chandra A; Sharma A; Calingasan NY; White JM; Shurubor Y; Yang XW; Beal MF; Johri A
    Hum Mol Genet; 2016 Jun; 25(11):2269-2282. PubMed ID: 27008868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
    Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
    Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease.
    Chen LW; Horng LY; Wu CL; Sung HC; Wu RT
    Neuropharmacology; 2012 Sep; 63(4):719-32. PubMed ID: 22633948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.
    Wenz T; Diaz F; Spiegelman BM; Moraes CT
    Cell Metab; 2008 Sep; 8(3):249-56. PubMed ID: 18762025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PGC-1α, mitochondrial dysfunction, and Huntington's disease.
    Johri A; Chandra A; Flint Beal M
    Free Radic Biol Med; 2013 Sep; 62():37-46. PubMed ID: 23602910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
    Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
    Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease.
    Ho DJ; Calingasan NY; Wille E; Dumont M; Beal MF
    Exp Neurol; 2010 Sep; 225(1):74-84. PubMed ID: 20561979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired PGC-1alpha function in muscle in Huntington's disease.
    Chaturvedi RK; Adhihetty P; Shukla S; Hennessy T; Calingasan N; Yang L; Starkov A; Kiaei M; Cannella M; Sassone J; Ciammola A; Squitieri F; Beal MF
    Hum Mol Genet; 2009 Aug; 18(16):3048-65. PubMed ID: 19460884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
    Tsunemi T; Ashe TD; Morrison BE; Soriano KR; Au J; Roque RA; Lazarowski ER; Damian VA; Masliah E; La Spada AR
    Sci Transl Med; 2012 Jul; 4(142):142ra97. PubMed ID: 22786682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice.
    Yatsuga S; Suomalainen A
    Hum Mol Genet; 2012 Feb; 21(3):526-35. PubMed ID: 22012983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
    Chiang MC; Chern Y; Juo CG
    Biochim Biophys Acta; 2011 Sep; 1812(9):1111-20. PubMed ID: 21651979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
    Hathorn T; Snyder-Keller A; Messer A
    Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
    Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
    Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function.
    Romanino K; Mazelin L; Albert V; Conjard-Duplany A; Lin S; Bentzinger CF; Handschin C; Puigserver P; Zorzato F; Schaeffer L; Gangloff YG; Rüegg MA
    Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20808-13. PubMed ID: 22143799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial biogenesis and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) deacetylation by physical activity: intact adipocytokine signaling is required.
    Li L; Pan R; Li R; Niemann B; Aurich AC; Chen Y; Rohrbach S
    Diabetes; 2011 Jan; 60(1):157-67. PubMed ID: 20929977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
    Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
    Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.
    Viscomi C; Bottani E; Civiletto G; Cerutti R; Moggio M; Fagiolari G; Schon EA; Lamperti C; Zeviani M
    Cell Metab; 2011 Jul; 14(1):80-90. PubMed ID: 21723506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
    Chiang MC; Chern Y; Huang RN
    Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.